A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)
Conditions
Malignant Melanoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Highlands Oncology Group ( Site 4042), Springdale, Arkansas, United States
UCSF Medical Center at Mission Bay ( Site 4044), San Francisco, California, United States
John Theurer Cancer Center at Hackensack University Medical Center ( Site 4047), Hackensack, New Jersey, United States
Inova Schar Cancer Institute ( Site 4046), Fairfax, Virginia, United States
Fred Hutchinson Cancer Center ( Site 4041), Seattle, Washington, United States
Blacktown Hospital ( Site 2001), Blacktown, New South Wales, Australia
Melanoma Institute Australia ( Site 2000), Wollstonecraft, New South Wales, Australia
One Clinical Research ( Site 2002), Nedlands, Western Australia, Australia
William Osler Health System (Brampton Civic Hospital) ( Site 2023), Brampton, Ontario, Canada
Sunnybrook Research Institute ( Site 2022), Toronto, Ontario, Canada
Centre Hospitalier Universitaire de Nice - Hôpital l'Archet-Dermatology Department ( Site 2042), Nice, Alpes-Maritimes, France
Hôpital Saint-Louis ( Site 2041), Paris, Île-de-France Region, France
Gustave Roussy ( Site 2040), Villejuif, Île-de-France Region, France
NCT ( Site 2065), Heidelberg, Baden-Wurttemberg, Germany
Universitätsklinikum Frankfurt Goethe-Universität ( Site 2063), Frankfurt am Main, Hesse, Germany
Universitaetsklinikum Koeln ( Site 2064), Cologne, North Rhine-Westphalia, Germany
Universitaetsklinikum Essen ( Site 2061), Essen, North Rhine-Westphalia, Germany
Universitaetsklinikum Hamburg-Eppendorf ( Site 2060), Hamburg, Germany
General Hospital of Athens "Laiko" ( Site 2080), Athens, Attica, Greece
Metropolitan Hospital ( Site 2082), Athens, Attica, Greece
European Interbalkan Medical Center ( Site 2081), Thessaloniki, Greece
HaEmek Medical Center ( Site 3003), Afula, Israel
Hadassah Medical Center ( Site 3001), Jerusalem, Israel
Rabin Medical Center ( Site 3002), Petah Tikva, Israel
Sheba Medical Center ( Site 3000), Ramat Gan, Israel
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 3021), Milan, Milano, Italy
Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 3020), Naples, Italy
Istituto Oncologico Veneto IRCCS ( Site 3022), Padova, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore ( Site 3023), Roma, Italy
Harbour Cancer & Wellness ( Site 3040), Auckland, New Zealand
Uniwersytecki Szpital Kliniczny w Poznaniu ( Site 3061), Poznan, Greater Poland Voivodeship, Poland
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 3060), Warsaw, Masovian Voivodeship, Poland
Unidade Local de Saude Lisboa Ocidental - Hospital de São Francisco Xavier ( Site 4002), Lisbon, Lisbon District, Portugal
Unidade Local de Saude de Santa Maria - Hospital de Santa Maria ( Site 4001), Lisbon, Portugal
Instituto Português de Oncologia do Porto Francisco Gentil, EPE ( Site 4000), Porto, Portugal
Hospital Universitari Vall d'Hebron ( Site 3081), Barcelona, Spain
Hospital Clínic Barcelona ( Site 3080), Barcelona, Spain
Hospital Universitario Ramón y Cajal-Medical Oncology ( Site 3082), Madrid, Spain
Study leads
Medical Director
Study Director
Merck Sharp & Dohme LLC